Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLL-018 vs Tofacitinib in Active Rheumatoid Arthritis
NCT05133297Phase 2Completed
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd.
- Start
- Feb 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of girocitinib in rheumatoid arthritis (RA) (4 arms), sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd. Primary endpoint: American College of Rheumatology 50% Response at 12 weeks. Started Feb 2022; status: completed.
02
Drugs
girocitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05133297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05133297.